12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Levotofisopam S-tofisopam: Phase IIa data

Data from 13 patients in an open-label, U.S. Phase IIa trial showed that 50 mg levotofisopam led to a mean percent reduction in sUA from baseline to day 7, the primary endpoint, of 48.8%. On secondary endpoints, levotofisopam led to a mean absolute reduction in sUA from baseline to day 7 of 3.9 mg/dL to a mean treated...

Read the full 268 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >